Open for inclusion

A safety and efficacy study of adding low dose pegylated IFN-alpha 2b to standard dose dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia

Cancer type: Leukemia

Phase: I/II

Principal Investigator: Stentoft Jesper

Country: DK

Keywords: Denmark, Aarhus

Status: Inclusion completed

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01725204?term=nordcml007&rank=1